NO20072882L - Defekte influensaviruspartikler. - Google Patents
Defekte influensaviruspartikler.Info
- Publication number
- NO20072882L NO20072882L NO20072882A NO20072882A NO20072882L NO 20072882 L NO20072882 L NO 20072882L NO 20072882 A NO20072882 A NO 20072882A NO 20072882 A NO20072882 A NO 20072882A NO 20072882 L NO20072882 L NO 20072882L
- Authority
- NO
- Norway
- Prior art keywords
- influenza virus
- influenza
- defective
- nucleic acid
- provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16141—Use of virus, viral particle or viral elements as a vector
- C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
- C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Oppfinnelsen er relatert til området av influensavirus og vaksineringen mot influensa. Oppfinnelsen tilveiebringer en kondisjonelt defekt influensaviruspartikkel som har syv forskjellige influensa nukleinsyresegmenter. Oppfinnelsen tilveiebringer også en kondisjonelt defekt influensaviruspartikkel som mangler et influensa nukleinsyresegment valgt fra gruppen av segmenter hovedsakelig kodene for sur polymerase (PA), den basiske polymerasen I (PB1) og den basiske polymerasen 2 (PB2). Nærmere bestemt tilveiebringer oppfinnelsen defekte influensaviruspartikler som har syv forskjellige influensa nukleinsyresegmenter og mangler et influensa nukleinsyresegment som hovedsakelig koder for sur polymerase. Videre tilveiebringer oppfinnelsen anvendelse av en sammensetning som omfatter en defekt influensaviruspartikkel i henhold til oppfinnelsen for produksjon av en farmasøytisk sammensetning rettet mot å generere immunologisk beskyttelse mot infeksjon av et individ med et influensavirus, og tilveiebringer en fremgangsmåte for å generere immunologisk beskyttelse mot infeksjon av et individ med et influensavirus som omfatter å tilveiebringe et individ med behov derav med en sammensetning som omfatter slik defekt influensaviruspartikkel.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04105696 | 2004-11-11 | ||
US62687804P | 2004-11-12 | 2004-11-12 | |
EP05105708 | 2005-06-27 | ||
US69443105P | 2005-06-28 | 2005-06-28 | |
PCT/EP2005/055808 WO2006051069A2 (en) | 2004-11-11 | 2005-11-08 | Defective influenza virus particles |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072882L true NO20072882L (no) | 2007-08-03 |
Family
ID=36228630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072882A NO20072882L (no) | 2004-11-11 | 2007-06-06 | Defekte influensaviruspartikler. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20080292658A1 (no) |
EP (2) | EP2272950A3 (no) |
JP (2) | JP4986859B2 (no) |
KR (1) | KR20070100882A (no) |
AU (1) | AU2005303817B8 (no) |
CA (1) | CA2587451A1 (no) |
IL (2) | IL182817A (no) |
MX (1) | MX2007005719A (no) |
NO (1) | NO20072882L (no) |
NZ (1) | NZ555118A (no) |
WO (1) | WO2006051069A2 (no) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL157003A0 (en) | 2001-01-19 | 2004-02-08 | Vironovative Bv | A virus causing respiratory tract illness in susceptible mammals |
EP1364006A2 (en) | 2001-02-23 | 2003-11-26 | Wisconsin Alumni Research Foundation | Methods to identify mutant cells with altered sialic acid |
BRPI0307679A2 (pt) | 2002-02-13 | 2016-11-08 | Wisconsin Alumni Res Found | vetor viral de influenza, vírus recombinate de influenza, molécula isolada de ácido nucleico e métodos para expressar um segmento heterólogo de ácido nucleico em uma célula e para preparar vírus semelhante a influenza incompetente na replicação. |
CN1646684B (zh) | 2002-02-21 | 2010-10-06 | 免疫医疗疫苗公司 | 重组副流感病毒表达系统以及包含源自间质肺病毒的异种抗原的疫苗 |
US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
WO2007135420A2 (en) * | 2006-05-24 | 2007-11-29 | The University Of Warwick | Defective interfering virus |
GB2437799B (en) * | 2006-05-24 | 2008-08-13 | Univ Warwick | Defective interfering virus |
CA2660038A1 (en) * | 2006-08-14 | 2008-06-19 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
US8597661B2 (en) | 2007-05-04 | 2013-12-03 | Wisconsin Alumni Research Foundation | Neuraminidase-deficient live influenza vaccines |
GB0822672D0 (en) | 2008-12-12 | 2009-01-21 | Univ Warwick | Anti-viral protection with viruses containing a defective genome |
EP2747778B1 (en) | 2011-08-26 | 2017-12-06 | Wisconsin Alumni Research Foundation | Influenza viruses with mutant pb2 gene segment as live attenuated vaccines |
CA2871160C (en) | 2012-05-10 | 2023-03-14 | Massachusetts Institute Of Technology | Agents for influenza neutralization |
CA2918739C (en) * | 2013-07-19 | 2021-09-07 | University Of Rochester | Attenuated influenza vaccines and uses thereof |
GB2522615A (en) | 2014-01-16 | 2015-08-05 | Univ Warwick | Assay and medicament |
WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
WO2016172588A1 (en) | 2015-04-24 | 2016-10-27 | Andrew Cox | Attenuated influenza vaccines and uses thereof |
EP3341018A1 (en) | 2015-08-28 | 2018-07-04 | Wisconsin Alumni Research Foundation | Generation of infectious influenza viruses from virus-like particles |
CL2018003871A1 (es) * | 2018-12-28 | 2021-01-15 | Univ Pontificia Catolica Chile | Anticuerpos monoclonales específicos para el antígeno pb2 del virus de la influenza humana (flu), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por flu |
CN113874496A (zh) | 2019-02-08 | 2021-12-31 | 威斯康星校友研究基金会(Warf) | 人源化细胞系 |
US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
WO2023138651A1 (en) * | 2022-01-19 | 2023-07-27 | Versitech Limited | Rationally designed single-round infectious virus and methods of use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166057A (en) * | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
ATE308612T1 (de) * | 1999-07-30 | 2005-11-15 | Isis Innovation | Als impfstoff verwendbares attenuiertes influenzavirus |
KR101169468B1 (ko) * | 2002-04-26 | 2012-08-01 | 메디뮨 엘엘씨 | 인플루엔자 바이러스의 생산을 위한 다중 플라스미드시스템 |
NZ540657A (en) * | 2002-12-13 | 2006-09-29 | Alphavax Inc | High-yielding, GMP-compatible, commercially feasible process for producing highly purified alphavirus replicon particle (ARP) preparations for use in human and veterinary medicine |
WO2004094466A2 (en) * | 2003-04-23 | 2004-11-04 | Wisconsin Alumni Research Foundation | Recombinant influenza viruses holding a mutation in a transmembrane protein gene |
-
2005
- 2005-11-08 NZ NZ555118A patent/NZ555118A/en not_active IP Right Cessation
- 2005-11-08 WO PCT/EP2005/055808 patent/WO2006051069A2/en active Application Filing
- 2005-11-08 KR KR1020077013149A patent/KR20070100882A/ko active IP Right Grant
- 2005-11-08 CA CA002587451A patent/CA2587451A1/en not_active Abandoned
- 2005-11-08 EP EP10182312A patent/EP2272950A3/en not_active Withdrawn
- 2005-11-08 US US11/667,594 patent/US20080292658A1/en not_active Abandoned
- 2005-11-08 MX MX2007005719A patent/MX2007005719A/es active IP Right Grant
- 2005-11-08 JP JP2007540638A patent/JP4986859B2/ja not_active Expired - Fee Related
- 2005-11-08 EP EP05801665A patent/EP1812564A2/en not_active Ceased
- 2005-11-08 AU AU2005303817A patent/AU2005303817B8/en not_active Ceased
-
2007
- 2007-04-26 IL IL182817A patent/IL182817A/en not_active IP Right Cessation
- 2007-06-06 NO NO20072882A patent/NO20072882L/no not_active Application Discontinuation
-
2012
- 2012-01-27 JP JP2012015022A patent/JP2012110339A/ja not_active Withdrawn
- 2012-02-20 IL IL218203A patent/IL218203A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2012110339A (ja) | 2012-06-14 |
MX2007005719A (es) | 2007-10-04 |
IL218203A0 (en) | 2012-04-30 |
JP2008519591A (ja) | 2008-06-12 |
EP2272950A3 (en) | 2011-07-20 |
US20080292658A1 (en) | 2008-11-27 |
AU2005303817B8 (en) | 2010-09-30 |
WO2006051069A3 (en) | 2006-07-20 |
AU2005303817B2 (en) | 2010-06-10 |
JP4986859B2 (ja) | 2012-07-25 |
AU2005303817A1 (en) | 2006-05-18 |
EP1812564A2 (en) | 2007-08-01 |
IL182817A (en) | 2012-04-30 |
NZ555118A (en) | 2009-09-25 |
EP2272950A2 (en) | 2011-01-12 |
CA2587451A1 (en) | 2006-05-18 |
WO2006051069A2 (en) | 2006-05-18 |
KR20070100882A (ko) | 2007-10-12 |
IL182817A0 (en) | 2007-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072882L (no) | Defekte influensaviruspartikler. | |
EP2078083A4 (en) | NEW DOG INFLUENZA VIRUS AND VEGETABLE THEREFOR | |
UA94717C2 (ru) | Модифицированный вирус гриппа, предназначенный для мониторинга и повышения эффективности вакцины | |
AU2009303758A8 (en) | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | |
MD3718565T2 (ro) | Vaccinuri împotriva virusului respirator | |
WO2007118206A3 (en) | Canine influenza virus | |
WO2007126810A3 (en) | High titer recombinant influenza viruses for vaccines | |
TW200732476A (en) | Functional influenza virus like particles (VLPs) | |
GB2503066A8 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
MX2010003202A (es) | Metodo para producir virus de la gripe. | |
NO20082149L (no) | Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk | |
NO20082124L (no) | Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom | |
NO20090723L (no) | Kondenserte heterosykliske derivater og fremgangsmater for anvendelse | |
UA105777C2 (uk) | Фармацевтична композиція ефективного інгібітора вгс для перорального введення | |
EA202090984A1 (ru) | Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент | |
WO2011158044A3 (en) | Respiratory formulations containing p38 mapk inhibitors | |
DE602006013117D1 (de) | Nipah-virus-impfstoffe | |
NO20075961L (no) | Materialer og fremgangsmater til kontroll av respiratorisk sykdom hos hundedyr | |
TW200738230A (en) | Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine | |
JP2009511080A5 (no) | ||
EA201290897A1 (ru) | Вакцины для пандемического гриппа | |
GT201400027A (es) | Acuosa suspensión concentrada que comprende un ácido sal de dodecilguanidina | |
DK1511489T3 (da) | Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A | |
AR059005A1 (es) | Virus quimericos del dengue | |
WO2013021284A3 (en) | Anti-il-6 vaccine composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: ABBOT BIOLOGICALS BV, NL Owner name: ERASMUS UNIVERSITY MEDICAL CENTER, NL |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |